A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: A double-blinded, randomised controlled trial

Critical Care

Volumn 17, Issue 2, 2013, Pages

  Robinson, Sian ^a   Zincuk, Aleksander ^a   Larsen, Ulla Lei ^a   Ekstrøm, Claus ^b   Nybo, Mads ^a   Rasmussen, Bjarne ^a   Toft, Palle ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ENOXAPARIN; FIBRINOGEN; ANTICOAGULANT AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ANTICOAGULANT THERAPY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION; AGED; CRITICAL ILLNESS; DOSE RESPONSE; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 84876292637     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12684     Document Type: Article

References (23)

1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW,. American College of Chest Physicians Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:381S-453S. 10.1378/chest.08-0656, 18574271, American College of Chest Physicians.
2. Shorr AF, Williams MD. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 2009, 101:139-144.
3. Cook DJ, Crowther MA. Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med 2010, 38:S76-S82.
4. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011, 364:1305-1314. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group.
5. Chan CM, Shorr AF. Venous thromboembolic disease in the intensive care unit. Semin Respir Crit Care Med 2010, 31:39-46. 10.1055/s-0029-1246283, 20101546.
6. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH,. American College of Chest Physicians Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e195S-e226S. 10.1378/chest.11-2296, 3278052, 22315261, American College of Chest Physicians.
7. Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 2007, 13:409-413.
8. Noble S, Peters DH, Goa KL. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995, 49:388-410. 10.2165/00003495-199549030-00006, 7774513.
9. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002, 72:308-318. 10.1067/mcp.2002.127114, 12235452.
10. Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, Lee KA, Cook RJ. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005, 20:357-363. 10.1016/j.jcrc.2005.09.009, 16310608.
11. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989, 62:940-944.
12. Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?. Crit Care Med 2003, 31:1405-1409. 10.1097/01.CCM.0000059725.60509.A0, 12771610.
13. Robinson S, Zincuk A, Strom T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 2010, 14:R41. 10.1186/cc8924, 2887151, 20298591.
14. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000, 161:1109-1114. 10.1164/ajrccm.161.4.9807025, 10764298.
15. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357:1191-1194. 10.1016/S0140-6736(00)04337-3, 11323066.
16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R,. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228. 10.1007/s00134-012-2769-8, 23361625, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup.
17. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg 1997, 85:874-885.
18. Riha GM, Van PY, Differding JA, Schreiber MA. Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. Am J Surg 2012, 203:598-602. 10.1016/j.amjsurg.2011.12.008, 22521049.
19. Mayr AJ, Dünser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 2002, 105:201-204. 10.1016/S0049-3848(02)00028-2, 11927124.
20. Dörffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Büller HR, Levi M. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002, 359:849-850. 10.1016/S0140-6736(02)07920-5, 11897286.
21. Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, Rabbat CG, Geerts WH, Warkentin TE. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005, 20:348-353. 10.1016/j.jcrc.2005.09.008, 16310606.
22. Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 2007, 30:E93-E102.
23. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001, 21:218-234. 10.1592/phco.21.2.218.34112, 11213859.